Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 197

1.

Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.

Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, Mills EJ.

Clin Infect Dis. 2013 Apr;56(7):961-7. doi: 10.1093/cid/cis1031. Epub 2012 Dec 12. Review.

PMID:
23243171
[PubMed - indexed for MEDLINE]
Free Article
2.
3.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

PMID:
15461877
[PubMed - indexed for MEDLINE]
Free Article
4.

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.

Hartwell D, Jones J, Baxter L, Shepherd J.

Health Technol Assess. 2011 Apr;15(17):i-xii, 1-210. doi: 10.3310/hta15170. Review.

PMID:
21473834
[PubMed - indexed for MEDLINE]
Free Article
5.

Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.

Rosen I, Kori M, Eshach Adiv O, Yerushalmi B, Zion N, Shaoul R.

World J Gastroenterol. 2013 Feb 21;19(7):1098-103. doi: 10.3748/wjg.v19.i7.1098.

PMID:
23467199
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.

Jin YJ, Lee JW, Lee JI, Park SH, Park CK, Kim YS, Jeong SH, Kim YS, Kim JH, Hwang SG, Rim KS, Yim HJ, Cheong JY, Cho SW, Lee JS, Park YM, Jang JW, Lee CK, Sohn JH, Yang JM, Han S.

BMC Gastroenterol. 2013 Apr 29;13:74. doi: 10.1186/1471-230X-13-74.

PMID:
23627926
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.

Mach TH, Cieśla A, Warunek W, Janas-Skulina U, Cibor D, Owczarek D, Ciećko-Michalska I.

Pol Arch Med Wewn. 2011 Dec;121(12):434-9.

PMID:
22157768
[PubMed - indexed for MEDLINE]
Free Article
8.

Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.

Minami T, Kishikawa T, Sato M, Tateishi R, Yoshida H, Koike K.

J Gastroenterol. 2013 Feb;48(2):254-68. doi: 10.1007/s00535-012-0631-y. Epub 2012 Jul 12.

PMID:
22790350
[PubMed - indexed for MEDLINE]
9.

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.

Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, Shelton M, Kerkar N, Galoppo M, Pedreira A, Rodriguez-Baez N, Ciocca M, Lachaux A, Lacaille F, Lang T, Kullmer U, Huber WD, Gonzalez T, Pollack H, Alonso E, Broue P, Ramakrishna J, Neigut D, Valle-Segarra AD, Hunter B, Goodman Z, Xu CR, Zheng H, Noviello S, Sniukiene V, Brass C, Albrecht JK.

J Hepatol. 2010 Apr;52(4):501-7. doi: 10.1016/j.jhep.2010.01.016. Epub 2010 Feb 4.

PMID:
20189674
[PubMed - indexed for MEDLINE]
10.

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.

Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, Gluud C, Gluud LL.

Cochrane Database Syst Rev. 2014 Feb 28;2:CD005441. Review.

PMID:
24585509
[PubMed - indexed for MEDLINE]
11.

Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.

Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, Daurès JP, Blanc P.

Drugs. 2013 Mar;73(3):263-77. doi: 10.1007/s40265-013-0027-1. Review.

PMID:
23436591
[PubMed - indexed for MEDLINE]
12.

Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials.

Fabrizi F, Dixit V, Martin P, Messa P.

J Viral Hepat. 2011 Jul;18(7):e263-9. doi: 10.1111/j.1365-2893.2010.01405.x. Epub 2010 Nov 25.

PMID:
21108701
[PubMed - indexed for MEDLINE]
13.

Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review.

Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R.

Ann Intern Med. 2013 Jan 15;158(2):114-23. Review.

PMID:
23437439
[PubMed - indexed for MEDLINE]
14.

Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.

Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F; SMIEC II Investigators.

Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c.

PMID:
18679072
[PubMed - indexed for MEDLINE]
15.

[Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia].

Božić M, Bojović K, Fabri M, Nožić D, Trkulja B, Milošević I.

Srp Arh Celok Lek. 2012 Jul-Aug;140(7-8):448-55. Serbian.

PMID:
23092029
[PubMed - indexed for MEDLINE]
16.

Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials.

Singal AK, Jampana SC, Anand BS.

Dig Dis Sci. 2011 Aug;56(8):2221-6. doi: 10.1007/s10620-011-1765-0. Epub 2011 Jun 4. Review.

PMID:
21643737
[PubMed - indexed for MEDLINE]
17.

Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

New Microbiol. 2005 Jan;28(1):13-21.

PMID:
15782622
[PubMed - indexed for MEDLINE]
18.

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.

Pessôa MG, Cheinquer H, Almeida PR, Silva GF, Lima MP, Paraná R, Lacerda MA, Parise ER, Pernambuco JR, Pedrosa SS, Teixeira R, Sette H Jr, Tatsch F.

Ann Hepatol. 2012 Jan-Feb;11(1):52-61.

PMID:
22166561
[PubMed - indexed for MEDLINE]
19.

The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.

Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, Rosenthal P, Mohan P, Balistreri WF, Narkewicz MR, Smith L, Lobritto SJ, Rossi S, Valsamakis A, Goodman Z, Robuck PR, Barton BA; Peds-C Clinical Research Network.

Gastroenterology. 2011 Feb;140(2):450-458.e1. doi: 10.1053/j.gastro.2010.10.047. Epub 2010 Oct 28.

PMID:
21036173
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials.

Chou R, Carson S, Chan BK.

J Viral Hepat. 2008 Aug;15(8):551-70. doi: 10.1111/j.1365-2893.2008.00984.x. Epub 2008 May 14. Erratum in: J Viral Hepat. 2009 May;16(5):376.

PMID:
18482285
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk